Cacnex has been committed to promoting a fast track for cross-border licensing and marketing of new drugs and medical devices between Chinese and North American enterprises, as well as asset acquisitions.​

 

Cacnex has established cooperative relations with hundreds of biotech and pharmaceutical enterprises in the US, Canada and China.

 

Through professional understanding of their corporate strategies, key technologies and product pipelines, we have explored potential cooperation points of good commercial value between the North American and Chinese Biomedical enterprises.​

 

Not only in the area of transactions, Cacnex is better at improving the commercial value of the assets through licensing and partnering development.

​

By closely working with local governments and regulatory agencies in the healthcare industry, Cacnex facilitates foreign pharma and biotech firms to introduce their new drugs or medical devices rapidly into the China market through a fast track process and partnership.